Stock listing

NASDAQ:OCGN Ocugen, Inc. Stock

Home listing (NASDAQ) of Ocugen, Inc.

Follow Ocugen, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:OCGN

$0.814 USD -0.028 (-3.3%)

Delayed at least 15 minutes · 4:44 PM EDT, Oct 15, 2026

Ocugen, Inc. logo
Ticker
NASDAQ:OCGN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Ocugen (NASDAQ:OCGN) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 8:30 AM ET

    Watch Transcript

  • Ocugen (NASDAQ:OCGN) Q1 2026 Earnings Call

    Tue, May 05, 2026 · 8:30 AM ET

    Watch Transcript

  • Ocugen (NASDAQ:OCGN) Q4 2025 Earnings Call

    Wed, Mar 04, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Oct 14, 2026

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

Oct 6, 2026

Ocugen to Participate in Upcoming Scientific Conferences

Sep 30, 2026

Ocugen to Participate in Upcoming October Investor and Industry Conferences

Sep 29, 2026

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

Sep 25, 2026

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Sep 1, 2026

Ocugen to Participate in Upcoming September Investor and Industry Conferences

Aug 25, 2026

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Aug 6, 2026

Ocugen to Participate in Upcoming August Investor Conferences

Jul 31, 2026

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

Jul 30, 2026

All Ocugen, Inc. news

Decks

Ocugen, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
38 in the last 12 months · 272 in all · newest Oct 14, 2026 · oldest 2019
Calls
22 calls with a replay · 22 with a transcript · latest Aug 6, 2026
Decks
74 decks · latest Oct 15, 2026

Where Ocugen, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:OCGN · Home listing · This pageNASDAQUnited StatesUSD
gettex:2H51gettexGermanyEUR
Tradegate:2H51TradegateGermanyEUR
LS Exchange:A2PSZHLS ExchangeGermanyEUR
BMV:OCGNBMVMexicoMXN
Lang & Schwarz:A2PSZHLang & SchwarzGermanyEUR
Frankfurt:2H51FrankfurtGermanyEUR
Stuttgart:2H51StuttgartGermanyEUR
Munich:2H51MunichGermanyEUR
Dusseldorf:2H51DusseldorfGermanyEUR
BOATS:OCGNBOATSUnited StatesUSD
BIVA:OCGNBIVAMexicoMXN
Hamburg:2H51HamburgGermanyEUR

Log in to ask 6ix AI your own questions about Ocugen, Inc.